Approval · Notice of Compliance 708 · 2002
NEFAZODONE: Notice of Compliance 708
Issued September 9, 2002
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 708
- Date
- September 9, 2002
- Company
- Pharmel Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- New manufacturer and product name
- Therapeutic class
- Antidepressant
- Canadian reference product
- SERZONE (Bristol-Myers Squibb Canada)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NEFAZODONE | 02246548 | — |
| NEFAZODONE | 02246549 | — |
| NEFAZODONE | 02246550 | — |
| NEFAZODONE | 02246551 | — |
Medicinal ingredients
- NEFAZODONE HCL 50 MG per TAB
- NEFAZODONE HCL 100 MG per TAB
- NEFAZODONE HCL 150 MG per TAB
- NEFAZODONE HCL 200 MG per TAB